Non-Monoamine-Based Approach for the Treatment of Depression and Anxiety Disorders
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Although currently prescribed antidepressants with actions mediated through alteration of monoaminergic transmission have been proven to be useful for the treatment of depressive and anxiety disorders, they are far from ideal due to their slow onset of action and low rate of responses. Although the brain monoamine systems have long been the focus of drug therapy for depression and anxiety disorders, current drug discovery has aimed at new molecular targets outside the monoamine systems to overcome these problems. Recent increase in understanding of the molecular mechanisms of depression and anxiety has provided alternative molecular targets for these disorders. In particular, receptors within the glutamate, γ-aminobutyric acid and neuropeptide systems provide a diversity of drug targets, and molecular biological and behavioral studies of these receptors have revealed the important roles they play in depression and anxiety. Here, we review recent patents and advances in research on these emerging molecular targets for the treatment of depression and anxiety, and discuss their advantages over currently used antidepressants and anxiolytics. Keywords: Antidepressant, anxiolytic, group I mGluR antagonist, group II mGluR agonist, group II mGluR antagonist, AMPA potentiator, GABAB positive modulator, GABAB antagonist, NK1 antagonist, NK2 antagonist, CRF1 antagonist, V1a antagonist, V1b antagonist, MCH1R antagonist, MC4 anatgonist
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485
Zobel, A. W., Nickel, T., Künzel, H. E., Ackl, N., Sonntag, A., Ising, M., & Holsboer, F. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(00)00016-9 · Cited by 705
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
Bielsky, I. F., Hu, S.-B., Szegda, K. L., Westphal, H., & Young, L. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300360 · Cited by 531
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471
Regulation of adult neurogenesis by antidepressant treatment
Duman, R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00358-x · Cited by 463
Targeting melanocortin receptors as a novel strategy to control inflammation
Catania, A., Gatti, S., Colombo, G., & Lipton, J. M. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.1 · Cited by 438
Purba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433
Glutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408
Vasopressin V1b receptor knockout reduces aggressive behavior in male mice
Wersinger, S. R., Ginns, E. I., O'Carroll, A.-M., Lolait, S. J., & Young III, W. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001195 · Cited by 397
Cited by
Emerging role of glutamate in the pathophysiology of major depressive disorder
Hashimoto, K. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.005 · Cited by 381
Behavioral effects of neuropeptides in rodent models of depression and anxiety
Rotzinger, S., Lovejoy, D. A., & Tan, L. A. (2010) · Peptides · doi:10.1016/j.peptides.2009.12.015 · Cited by 211
An update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Vasopressin V1B receptor antagonists as potential antidepressants
Chaki, S. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab013 · Cited by 34
Self-citationAhnaou, A., Ver Donck, L., & Drinkenburg, W. H. I. M. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.003 · Cited by 31
Metadata
- Authors
- Chaki, S., Okubo, T., & Sekiguchi, Y.
- Venue
- Recent Patents on CNS Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2006-01-01
- Volume
- 1
- Issue
- 1
- Pages
- 1-27
- ISSN
- 1574-8898 (ISSN-L)
- OpenAlex
- W2120003024
- Cited by
- 39
- References
- 18
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-Monoamine-Based Approach for the Treatment of Depression and Anxiety Disorders. https://app.cochat.ai/papers/10.2174/157488906775245318
- The paper
- Chaki, S., Okubo, T., & Sekiguchi, Y. (2006). Non-Monoamine-Based Approach for the Treatment of Depression and Anxiety Disorders. Recent Patents on CNS Drug Discovery. https://doi.org/10.2174/157488906775245318
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.